相关实验视频
Updated: Jan 22, 2026

05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.2K
从MAiD转诊到向治疗的成功:一个BRAF突变无塑性甲状腺癌的案例
Brett Stubbert1, Paul Stewart1,2, Eric Winquist1,2
1Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.
Reports (MDPI)
|January 21, 2026
概括
下一代测序 (NGS) 在初始IHC测试阴性后,在形甲状腺癌 (ATC) 中发现了BRAF V600E突变. 这导致了向治疗,将患者的生存时间延长了七个月.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 医学诊断 医学诊断 医学诊断
背景情况:
- 无塑性甲状腺癌 (ATC) 具有攻击性,平均存活时间为4-10个月.
- 在ATC中,BRAF突变是新疗法的关键标.
- 诊断的准确性对于及时启动治疗至关重要.
研究的目的:
- 报告一个ATC病例,NGS发现BRAF突变被IHC遗漏.
- 突出ATC中先进分子诊断的临床影响.
- 讨论在单一付款者系统中获得针对性治疗的挑战.
主要方法:
- 一个有症状的ATC患者的病例报告.
- 通过免疫组织化学 (IHC) 进行初始BRAF突变测试.
- 随后通过下一代测序 (NGS) 进行BRAF突变测试.
- 用向疗法 (达布拉费尼布-特拉美丁尼布) 和免疫疗法 (佩姆布罗利祖马布) 的治疗.
主要成果:
- 对BRAF突变的IHC测试最初是负的.
- 国家基因系统证实了V600E BRAF突变.
- 向治疗将患者的生存时间延长了近七个月.
- 患者的寿命延长了近七个月.
结论:
- 在ATC中检测BRAF突变时,NGS表现出比IHC更高的灵敏度.
- 快速,全面的诊断对于有效的ATC治疗至关重要.
- 在某些医疗保健系统中,获得新型疗法可能是复杂的.
相关概念视频
Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
Cancer Therapies
9.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Ecological Succession
21.3K
Ecological succession is influenced by the processes of facilitation, inhibition, and toleration. Facilitation occurs when early successional species create more favorable ecological conditions for subsequent species, such as enhanced nutrient, water, or light availability. In contrast, inhibition happens when early successional species create unfavorable ecological conditions for potential successive species, such as limiting resource availability. In some cases, later successional species...
21.3K
Mutations
94.4K
Overview
94.4K
Cancers Originate from Somatic Mutations in a Single Cell
14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Viral Mutations
39.8K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K

